Answers are grounded in this paper and cite their sources.
BACKGROUND: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, anovulation, chronic inflammation, and oxidative stress. Current treatments mainly relieve symptoms without addressing ovarian damage. Human umbilical cord–derived mesenchymal stem cell (hUC-MSC) secretome is a cell-free product with anti-inflammatory, antioxidant, and regenerative effects that avoids cell-related risks, but its role in PCOS remains unclear. This study was conducted to evaluate its effects on ovarian tumor necrosis factor (TNF)-α, oxidative stress, and serum estradiol in letrozole-induced PCOS rats.METHODS: Thirty female Wistar rats were assigned to a normal group, untreated PCOS-induced group, and PCOS-induced groups treated with either 200, 300, or 400 µL hUC-MSC secretome. PCOS was induced with letrozole for 21 days, and confirmed by vaginal cytology on day-22. Ovarian TNF-α expression, serum estradiol, ovarian malondialdehyde (MDA), and ovarian superoxide dismutase (SOD) activity were measured using reverse transcription quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), the thiobarbituric acid reactive substances (TBARS) assay, and the water-soluble tetrazolium salt (WST) assay, respectively.RESULTS: Letrozole successfully induced PCOS characteristics, which was marked by persistent diestrus and ovarian histological alterations in PCOS-induced groups. Compared with the untreated PCOS group, group receiving 200 µL hUC-MSC secretome showed lower ovarian TNF-α expression and MDA levels, as well as higher SOD activity and serum estradiol concentrations, approaching normal control values, although these differences were not statistically significant. Compared with the other hUC-MSC concentrations, the 200 µL dose showed the most consistent trend across inflammatory, oxidative stress, and hormonal parameters.CONCLUSION: Administration of hUC-MSC secretome, especially 200 µL dose, showed a trend toward reduced ovarian inflammation and oxidative stress in PCOS rats. These findings suggest that hUC-MSC secretome may have potential as a complementary treatment for PCOS.
No takes yet. Share an insight, caveat, or question.
Widyasuri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: